Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

P&G/Cygnus

This article was originally published in The Tan Sheet

Executive Summary

Announce agreement to develop an as-yet-unnamed consumer product using a Cygnus drug delivery system on Oct. 25. The product, which will not make use of a transdermal system, will be manufactured by Cygnus and marketed exclusively by P&G worldwide. Cygnus said the product is not expected to require FDA approval and that its controlled-release technologies are applicable for cough/sore throat medicines and nasal sprays as well as oral hygiene products. P&G plans to undertake consumer testing with prototypes of the product during the next year. Cygnus said it is currently negotiating with P&G and several other firms to develop additional consumer products, while P&G noted that it is in discussions with Cygnus regarding "several other delivery systems for a variety of markets".
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS082088

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel